[Skip to Navigation]
Comment & Response
October 27, 2021

Biomarkers for Myocardial Infarction Type Discrimination—The Key Might Be in the Time Course of the Disease

Author Affiliations
  • 1Cardiac Intensive Care Unit, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France
  • 2Department of Cardiology and Interventional Cardiology, Hôpital Cardiologique Louis Pradel, Université Claude-Bernard, Inserm UMR 1060, Lyon, France
JAMA Cardiol. 2022;7(1):112-113. doi:10.1001/jamacardio.2021.4398

To the Editor We read with great interest the study conducted by Nestelberger et al1 bringing valuable information in a growing field of translational medicine. As stated by the authors, early discrimination of myocardial infarction (MI) type is of major importance and remains an everyday clinical challenge. They reported early biomarkers to provide modest discrimination in the early diagnosis of MI but stressed the importance of models combining clinical findings and selected biomarkers. We would like to address some comments related to the subject.

Add or change institution